Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.

Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan-Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan-Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients.

Journal of clinical medicine. 2019 Apr 11*** epublish ***

Shinichi Sakamoto, Maihulan Maimaiti, Minhui Xu, Shuhei Kamada, Yasutaka Yamada, Hiroki Kitoh, Hiroaki Matsumoto, Nobuyoshi Takeuchi, Kosuke Higuchi, Haruhito A Uchida, Akira Komiya, Maki Nagata, Hiroomi Nakatsu, Hideyasu Matsuyama, Koichiro Akakura, Tomohiko Ichikawa

Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. ., Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. ., Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. ., Department of Urology, Yokohama Rosai Hospital, Yokohama 222-0036, Japan. ., Department of Urology, Asahi Central Hospital, Aashi 289-2511, Japan. ., Department of Urology, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Shinjyuku 162-8543, Japan. ., Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube 755-0046, Japan. ., Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. ., Department of Urology, Funabashi Medical Center, Funabashi 273-8588, Japan. ., Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-0914, Japan. ., Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. ., Department of Urology, Yokohama Rosai Hospital, Yokohama 222-0036, Japan. ., Department of Urology, Asahi Central Hospital, Aashi 289-2511, Japan. ., Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube 755-0046, Japan. ., Department of Urology, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Shinjyuku 162-8543, Japan. ., Department of Urology, Chiba University Hospital, Chiba 260-8670, Japan. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe